依普利酮（Planep）纳入医保了吗？

Eplerenone (alias: Planep, Inspra) is a new generation of selective aldosterone antagonist. Eplerenone can be used alone or in combination with other antihypertensive drugs for the treatment of hypertension. It also has a good antihypertensive effect on simple systolic hypertension and has a good antihypertensive effect on diet-induced obesity-related hypertension.

In addition, eplerenone can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for hypertensive patients with diabetes.

In 2002, eplerenone was approved for clinical use by the State Food and Drug Administration. Has eplerenone (Planep) been included in medical insurance?

It is understood that eplerenone is approved for clinical treatment, but it has not yet been officially launched in China. Therefore, there is no medical insurance to speak of!

According to Medical Travel, India’s Lupine Pharmaceuticals sells eplerenone 50mg × 100 tablets for about $500. Since exchange rates fluctuate and prices are not fixed, please consult Medical Travel for specific prices.

Eplerenone treats patients with stage 1 and stage 2 hypertension with high efficiency and similar potency in reducing diastolic blood pressure and systolic blood pressure as enalapril.

Eplerenone also has a good blood pressure lowering effect in patients with essential hypertension with low renin levels for whom angiotensin 2-converting enzyme inhibitors and angiotensin 2Ⅱ protein kinase inhibitors are not effective. It also has a good blood pressure lowering effect on simple systolic hypertension, and has a good blood pressure lowering effect on obesity-related hypertension caused by diet.

For severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone (alias: Planep, Inspra) can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. Combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve patients' quality of life and reduce mortality in severe heart failure and myocardial infarction.